Leading up to Immunogenicity for Biotherapeutics this April 17-19, 2012 in Washington, DC, we'll be highlighting some of the key sessions at this year's conference. Today, we're looking at Considerations for the Development of an Immunogenicity Risk Assessment for a PEGylated Endogenous Therapeutic.Today's featured session focuses on the underlying causes of an immune response, through anticipating the changes in binding and retention of the engineered molecules these scientists are creating / working with. After attending this session, participants will have a better understanding of how to design specific therapies taking advantage of new improvements in molecular structure that make them less likely to trigger an immune response.
If you'd like to know more about Immunogenicity for Biotherapeutics, download the brochure. You may also join the LinkedIn Group to receive an exclusive code to save 25% off the standard rate. If you have any further questions, feel free to email Jennifer Pereira.
Featured Session: Considerations for the Development of an Immunogenicity Risk Assessment for a PEGylated Endogenous Therapeutic
Speaker: Robin Marsden, PhD, Scientist, AMBRX
About the Session:
• Anticipate the changes in binding and retention of your macromolecule
• Design therapies that can take advantage of these induced improvements in PK and PD
• Properly value and incorporate information from transgenic animal models
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment